Short-course chemotherapy of tuberculosis with largely twice-weekly isoniazid-rifampin.
Although short-course, largely twice weekly chemotherapy for treatment of tuberculosis has been shown to be effective in other countries, when given under closely controlled conditions, it has not been adopted in this country where most patients are older and are treated as outpatients. Since January, 1976, 315 patients (mean age 55.5 years) with proven pulmonary tuberculosis have been treated with rifampin (RIF) 600 mg and isoniazid (INH) 300 mg daily for one month, followed by RIF 600 mg and INH 900 mg twice-weekly for another eight months, self-administered except for a few patients. By three months, 95 percent had converted to negative culture. There were only ten failures among 185 patients in whom final results could be assessed. There has been only one relapse during 1-21 months of follow-up in 175 patients. Serious side effects were few: six instances of jaundice, two of "flu-like syndrome," and one of thrombocytopenia. This form of initial therapy for tuberculosis is safe, effective, and economical.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004342:Drug Hypersensitivity / Q000209:etiology; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007565:Jaundice / Q000139:chemically induced; D008875:Middle Aged; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D007538:Isoniazid; D012293:Rifampin